Skip to main content


Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

Fig. 3

CV events. Data presented for the overall population, the subgroup of patients with a history of CVD (CVD history) and the subgroup of elderly patients aged ≥65 years with a history of CVD and hypertension (Elderly patients with CVD risk). n is the number of patients with an event; N is number of patients in treatment group. CI confidence interval, CTRL control, CV cardiovascular, CVD CV disease, DAPA dapagliflozin, HR hazard ratio, p–y = patient years

Back to article page